AI assistant
Cartesian Therapeutics, Inc. — Director's Dealing 2016
Jun 22, 2016
33483_dirs_2016-06-21_2b639451-cc3b-4392-8688-5607bb9ece3a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-06-21
Reporting Person: TAS Partners, LLC (Director, 10% Owner)
Reporting Person: Leukon Investments, LP (Director, 10% Owner)
Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 21013 | Indirect |
| Common Stock | 19702 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series B Convertible Preferred Stock | $ | Common Stock (157864) | Indirect | ||
| Series B Convertible Preferred Stock | $ | Common Stock (157864) | Indirect | ||
| Series C Convertible Preferred Stock | $ | Common Stock (153742) | Indirect | ||
| Series C Convertible Preferred Stock | $ | Common Stock (93954) | Indirect | ||
| Series D Convertible Preferred Stock | $ | Common Stock (63547) | Indirect | ||
| Series D Convertible Preferred Stock | $ | Common Stock (51355) | Indirect | ||
| Series E Convertible Preferred Stock | $ | Common Stock (84421) | Indirect | ||
| Series E Convertible Preferred Stock | $ | Common Stock (79156) | Indirect | ||
| Common Warrants | $17.55 | 2018-07-24 | Common Stock (5326) | Indirect | |
| Common Warrants | $17.55 | 2018-07-24 | Common Stock (4304) | Indirect |
Footnotes
F1: Held by Leukon Investments LP ("Leukon").
F2: Held by TAS Partners, LLC ("TAS").
F3: The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
F4: LKST, Inc. is the general partner of Leukon. Timothy Springer is the president of LKST, Inc. and the managing member of TAS. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.